ATE197903T1 - Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken - Google Patents

Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken

Info

Publication number
ATE197903T1
ATE197903T1 AT93912042T AT93912042T ATE197903T1 AT E197903 T1 ATE197903 T1 AT E197903T1 AT 93912042 T AT93912042 T AT 93912042T AT 93912042 T AT93912042 T AT 93912042T AT E197903 T1 ATE197903 T1 AT E197903T1
Authority
AT
Austria
Prior art keywords
carbohydrate
peptide
cell immunity
effect
immunogenic
Prior art date
Application number
AT93912042T
Other languages
English (en)
Inventor
Mikael Jondal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE197903T1 publication Critical patent/ATE197903T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT93912042T 1992-04-28 1993-04-23 Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken ATE197903T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv
PCT/SE1993/000353 WO1993021948A1 (en) 1992-04-28 1993-04-23 Peptide-carbohydrate conjugates generating t-cell immunity

Publications (1)

Publication Number Publication Date
ATE197903T1 true ATE197903T1 (de) 2000-12-15

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912042T ATE197903T1 (de) 1992-04-28 1993-04-23 Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken

Country Status (19)

Country Link
US (2) US5807559A (de)
EP (1) EP0675733B1 (de)
JP (1) JPH07506358A (de)
CN (1) CN1096032A (de)
AT (1) ATE197903T1 (de)
AU (1) AU676679B2 (de)
CA (1) CA2134097A1 (de)
DE (1) DE69329735T2 (de)
DK (1) DK0675733T3 (de)
ES (1) ES2155070T3 (de)
GR (1) GR3035501T3 (de)
IL (1) IL105503A (de)
IS (1) IS4010A (de)
MA (1) MA22885A1 (de)
MY (1) MY108864A (de)
PT (1) PT675733E (de)
SI (1) SI9300223A (de)
TN (1) TNSN93045A1 (de)
WO (1) WO1993021948A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
EP0969873B1 (de) * 1997-03-27 2006-06-07 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
WO1999048515A1 (en) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1073667A2 (de) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharid-antigen-konjugate
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
ES2267559T3 (es) 1999-08-20 2007-03-16 Sloan-Kettering Institute For Cancer Research Glicoconjugados, glicoamino, acidos sus intermediarios y el uso de los mismos.
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
EP1594898A2 (de) * 2003-02-06 2005-11-16 Tripep AB Glycosylierte spezifitätaustauscher
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
CN103038343A (zh) 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
EP2500033A1 (de) 2011-03-17 2012-09-19 Institut Pasteur Verfahren zur Herstellung mehrfacher Antigen-Glycopeptid-Kohlenhydratkonjugate
CA2837214C (en) 2011-06-28 2021-06-01 Inovio Pharmaceuticals, Inc. A minimally invasive dermal electroporation device
EP2606897A1 (de) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Zusammensetzungen für die Behandlung von Krankheiten, die von eingehüllten Viren verursacht werden
EP3651795A4 (de) * 2017-07-12 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur behandlung von krebs mit einer h3k27m-mutation
WO2020163695A1 (en) 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas System Aspergillus antigen chimeric receptors and use thereof
WO2020163682A1 (en) 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas System Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
AU634153B2 (en) * 1988-02-01 1993-02-18 Wyeth Holdings Corporation T-cell epitope as carriers molecule for conjugate vaccines
EP0400077A4 (en) * 1988-02-12 1990-12-27 The Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
FI920131A0 (fi) * 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
CA2067124A1 (en) * 1989-08-28 1991-03-01 Patricia L. Domen Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
EP0675733B1 (de) 2000-12-06
SI9300223A (en) 1994-03-31
CA2134097A1 (en) 1993-11-11
AU4274693A (en) 1993-11-29
GR3035501T3 (en) 2001-06-29
DK0675733T3 (da) 2001-05-07
IS4010A (is) 1993-10-29
DE69329735T2 (de) 2001-08-02
US6033669A (en) 2000-03-07
MY108864A (en) 1996-11-30
AU676679B2 (en) 1997-03-20
IL105503A (en) 1999-05-09
US5807559A (en) 1998-09-15
DE69329735D1 (de) 2001-01-11
CN1096032A (zh) 1994-12-07
IL105503A0 (en) 1993-08-18
EP0675733A1 (de) 1995-10-11
PT675733E (pt) 2001-05-31
ES2155070T3 (es) 2001-05-01
MA22885A1 (fr) 1993-12-31
TNSN93045A1 (fr) 1994-03-17
JPH07506358A (ja) 1995-07-13
WO1993021948A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
ATE197903T1 (de) Peptid-kohlenwasserstoff konjugate, welche t-zell immunität bewirken
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
NO933028D0 (no) Peg-interferonkonjugater
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
EP1003526A4 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendung
DE68906366D1 (en) Cd4-polypeptidderivate.
CO4930281A1 (es) Conjugados utiles en el tratamiento del cancer de prostata
TR199501654A2 (tr) Kimyasal bilesikler.
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
HUT65418A (en) Process for producing inclusion compounds of nimesulide with cyclodextrins and pharmaceutical preparatives containing them
DK0822808T3 (da) Kompositmateriale med natriumstivelsesglycolat som bærermateriale og produkter deraf
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.
ES2152315T3 (es) Xamoneline tartrato.
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
NO306292B1 (no) Triaryletylenderivater for anvendelse innen terapi
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
IT1274592B (it) Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
PT92379A (pt) Metodo para a sintese de derivados polipeptidicos
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee